| P50 | author | Namson S Lau | Q47335208 |
| P2093 | author name string | Nicholas R Fuller | |
| | Michael B Halstead | |
| | Arthur J Kaffes | |
| | John Wlodarczyk | |
| | Hoi-Poh Tee | |
| | Suzanne Pearson | |
| | Raman Chettiar | |
| P2860 | cites work | Long term pharmacotherapy for obesity and overweight: updated meta-analysis. | Q22242086 |
| | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| | Safety and Effectiveness of the Intragastric Balloon for Obesity. A Meta-Analysis | Q22252609 |
| | 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study | Q24633604 |
| | Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 |
| | Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey | Q29614468 |
| | Intragastric balloon in the treatment of patients with morbid obesity | Q34352785 |
| | Meta-analysis: pharmacologic treatment of obesity | Q34408897 |
| | Meta-analysis: the effect of dietary counseling for weight loss | Q34580804 |
| | Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study | Q34580894 |
| | Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin | Q44043319 |
| | A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin | Q44262737 |
| | Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis | Q44942311 |
| | Metabolic parameters after BioEnterics Intragastric Balloon placement in obese patients. | Q46027355 |
| | Impact on obesity-related illnesses and quality of life following intragastric balloon. | Q46240892 |
| | What are the benefits of moderate weight loss? | Q47279035 |
| | Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial | Q47336480 |
| | Long-term persistence of hormonal adaptations to weight loss | Q47347342 |
| | Intragastric balloon or diet alone? A retrospective evaluation | Q47703580 |
| | Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients | Q47782935 |
| | Gastric distension and gastric capacity in relation to food intake in humans | Q48950591 |
| | Intragastric balloon as an artificial bezoar for treatment of obesity | Q49099701 |
| | BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients. | Q50482823 |
| | Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. | Q51233480 |
| | What becomes of patients one year after the intragastric balloon has been removed? | Q51423205 |
| | Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. | Q51548921 |
| | Intragastric balloon for "non-morbid" obesity: a retrospective evaluation of tolerance and efficacy. | Q51678166 |
| | Development of a brief measure to assess quality of life in obesity. | Q53488539 |
| P433 | issue | 8 | |
| P921 | main subject | obesity | Q12174 |
| | metabolic syndrome | Q657193 |
| P304 | page(s) | 1561-1570 | |
| P577 | publication date | 2013-06-11 | |
| P1433 | published in | Obesity | Q15763232 |
| P1476 | title | An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study | |
| P478 | volume | 21 | |